5-Amino-1MQ vs SLU-PP-332: What the Research Shows
5-Amino-1MQ and SLU-PP-332 side by side: what they are, how they are regulated and what is still unknown.
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Quick verdict
Summary of studies, not a recommendationWhere the research points
Consider 5-Amino-1MQ if…
No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.
Consider SLU-PP-332 if…
No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.
What they have in common
- Only animal or lab studies of 5-amino-1MQ were found (e.g. obese mice): combined with a low-fat diet it promoted marked loss of adiposity and weight[2]
- Only animal or lab studies of SLU-PP-332 were found (e.g. mouse): In mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise effects on whole-body metabolism.[6]
Status labels come from public FDA and WADA records; see the sources below.
Side by side
Spec comparison
Showing 5 of 12 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026, WADA, Half-life, Evidence strength, US searches per month are the same or both unknown.
| Field | 5-Amino-1MQ | SLU-PP-332 |
|---|---|---|
| Class | NNMT inhibitor (not a peptide) | ERR agonist (not a peptide) |
| Also called | 5-amino, 1MQ | slupp, SLU-PP |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Not FDA approved · research chemical | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | WADA status unclear5-Amino-1MQ is not named. S4.4 covers AMPK activators, PPAR-delta agonists and Rev-erb agonists by example, and nothing there names an NNMT inhibitor. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. | WADA status unclearSLU-PP-332 is not named. S4.4 lists AMPK activators, PPAR-delta agonists and Rev-erb agonists; SLU-PP-332 is an ERR agonist, which the list does not mention. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. |
| Half-life | No published half-life foundPubMed search, 2 Oct 2026 | No published half-life foundPubMed search, 2 Oct 2026 |
| Evidence strength | Animal evidence, 2 of 4Strongest: Scientific reports 2022, PMID 35013352 | Animal evidence, 2 of 4Strongest: The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
| Human studies we summarised | 0 human (0 randomized or controlled) of 4 summarised | 0 human (0 randomized or controlled) of 7 summarised |
| Typical study doses |
| Not reported in study abstractsPubMed search, 2 Oct 2026 |
| Vial sizes sold | 5 mg, 10 mg | 5 mg |
| US searches per month | 27,100 · +60% searches | 27,100 · −38% searches |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Taken together?
5-Amino-1MQ and SLU-PP-332 together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Scientific reports · 2022PMID 35013352Accessed 2 Oct 2026
- 3Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021PMID 33645410Accessed 2 Oct 2026
- 4PubMed search: "5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab] (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: nicotinamide N-methyltransferase[tiab] AND (quinolinium[tiab] OR 5-amino-1MQ[tiab] OR "5-amino-1-methylquinolinium"[tiab] OR 5MQ[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 7PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("SLU-PP-332"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.